Hanxiao Y. You

300 Guangzhou Road
Nanjing, 210029, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Clinical and molecular characterization of ILD in patients with overlapping ASyS and SjD: a retrospective observational study.

Clinical and molecular characterization of ILD in patients with overlapping ASyS and SjD: a retrospective observational study.

Journal: Rheumatology (Oxford, England)

Published: June 18, 2025

Anti-MDA5 antibody IgG1 subtype is associated with rapidly progressive interstitial lung disease in anti-MDA5-positive dermatomyositis.

Anti-MDA5 antibody IgG1 subtype is associated with rapidly progressive interstitial lung disease in anti-MDA5-positive dermatomyositis.

Journal: Orphanet journal of rare diseases

Published: December 19, 2024

Low serum S100A6 levels are associated RP-ILD risk in anti-MDA5-positive dermatomyositis.

Low serum S100A6 levels are associated RP-ILD risk in anti-MDA5-positive dermatomyositis.

Journal: Clinical rheumatology

Published: June 18, 2024

Triple-combination therapy did not improve prognosis in anti-MDA5 positive dermatomyositis: a multicentre longitudinal cohort study.

Triple-combination therapy did not improve prognosis in anti-MDA5 positive dermatomyositis: a multicentre longitudinal cohort study.

Journal: Clinical and experimental rheumatology

Published: May 12, 2024

Proteomic profiling identifies SPP1 associated with rapidly progressive interstitial lung disease in anti-MDA5-positive dermatomyositis.

Proteomic profiling identifies SPP1 associated with rapidly progressive interstitial lung disease in anti-MDA5-positive dermatomyositis.

Journal: Arthritis research & therapy

Published: September 21, 2023

Efficacy and safety of iguratimod combined with methylprednisolone for primary Sjögren's syndrome: a meta-analysis and trial sequential analysis.

Efficacy and safety of iguratimod combined with methylprednisolone for primary Sjögren's syndrome: a meta-analysis and trial sequential analysis.

Journal: European review for medical and pharmacological sciences

Published: September 05, 2023

Rapidly progressive interstitial lung disease risk prediction in anti-MDA5 positive dermatomyositis: the CROSS model.

Rapidly progressive interstitial lung disease risk prediction in anti-MDA5 positive dermatomyositis: the CROSS model.

Journal: Frontiers in immunology

Published: September 01, 2023

Elevated serum B-cell activator factor levels predict rapid progressive interstitial lung disease in anti-melanoma differentiation associated protein 5 antibody positive dermatomyositis.

Elevated serum B-cell activator factor levels predict rapid progressive interstitial lung disease in anti-melanoma differentiation associated protein 5 antibody positive dermatomyositis.

Journal: Orphanet journal of rare diseases

Published: August 13, 2023

Development and external validation of a prediction model for venous thromboembolism in systemic lupus erythematosus.

Development and external validation of a prediction model for venous thromboembolism in systemic lupus erythematosus.

Journal: RMD open

Published: August 02, 2023

A multicenter, double-blind, randomized controlled clinical trial comparing ergometrine with oxytocin and oxytocin alone for prevention of postpartum hemorrhage at cesarean section

A multicenter, double-blind, randomized controlled clinical trial comparing ergometrine with oxytocin and oxytocin alone for prevention of postpartum hemorrhage at cesarean section

Journal: Zhonghua fu chan ke za zhi

Published: December 01, 2022

Coexistence of Anti-Ro52 Antibodies in Anti-MDA5 Antibody-Positive Dermatomyositis Is Highly Associated With Rapidly Progressive Interstitial Lung Disease and Mortality Risk.

Coexistence of Anti-Ro52 Antibodies in Anti-MDA5 Antibody-Positive Dermatomyositis Is Highly Associated With Rapidly Progressive Interstitial Lung Disease and Mortality Risk.

Journal: The Journal of rheumatology

Published: June 02, 2022

Prognostic factors of systemic lupus erythematosus patients with pulmonary embolism: An 11-year cohort study.

Prognostic factors of systemic lupus erythematosus patients with pulmonary embolism: An 11-year cohort study.

Journal: Lupus

Published: April 12, 2022

Showing 1-12 of 28

Last Updated: 09/26/2026